AOL News has a new home! The Huffington Post.
Click here to visit the new home of Politics Daily!(Oct. 11) -- A patient suffering from a spinal cord injury has become the first recipient of an experimental, and highly controversial, human embryonic stem cell treatment. Geron Corp., the biopharmaceutical group behind the phase I clinical trial, made the groundbreaking announcement earlier today. The company is the only one to have FDA approval for human embryonic stem cell trials. Little information about the patient has been released, but the Geron trial is designed to test the safety of embryonic stem cell therapy for newly sustained thoracic spinal cord injuries. "Initiating the ...
For the first time, human subjects will be used to test a treatment of spinal cord injuries derived from embryonic stem cells, under rules approved by the Food and Drug Administration. ...
For the first time, human subjects will be used to test a treatment of spinal cord injuries derived from embryonic stem cells, under rules approved by the Food and Drug Administration. The biopharmaceutical company Geron announced in a news release Friday that the FDA had lifted a hold on the clinical trial using human stem cells, The New York Times reported. The hold was put into place shortly after the FDA initially cleared the research in January 2009. Regulators became concerned when cysts were discovered in some mice injected with the stem cells. Geron had to run another study on mice ...
(July 30) -- The Food and Drug Administration has cleared biotech firm Geron to perform the first human trials of a medical treatment based on embryonic stem cells. Patients with recently sustained spinal cord injuries will be the first to undergo the company's stem cell therapy, called GRNOPC1. The trial was initially approved by the FDA in January 2009 but stalled shortly after due to safety concerns. Embryonic stem cells have been a focus of medical research in recent years because of their ability to be differentiated into any kind of cell. In this case, they'll be turned into precursors ...
Follow Politics Daily
POPULAR
News From Our Partners




Top News
More News
More on Aol
Local News
More Blog/Sites
Sites and Services